RxDoctor Payments Data

Jitender Munjal, MD

Clinical Cardiac Electrophysiology · Tucson, AZNPI 1417077603

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (38.2%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Biosense Webster, Inc. at 52.3% of the total.

$65,757in general payments, 2019–2025

Across 1,177 payments — averaging $55.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$34K
  • Boston Scientific$10K
  • Cvrx, Inc.$6K
  • Biotronik Inc.$3K
  • ZOLL Respicardia, Inc.$2K
  • Philips North America LLC$2K
  • plus $9K from 34 others

What the payments were for

  • Consulting fees$16,42425%
  • Grants$250%
  • Travel & lodging$23,51436%
  • Food & beverage$25,10638%
  • Education$6231%
  • Other$660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$65,757 in reported general payments places this provider in the 75th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$622,397
Medicare patients
2,265
Services billed
8,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban412$499,496
XareltoRivaroxaban269$314,362
EntrestoSacubitril/Valsartan100$139,512
JardianceEmpagliflozin91$117,797
Repatha SureclickEvolocumab12$20,273
MultaqDronedarone Hcl11$18,517
CorlanorIvabradine Hcl15$12,714
Dofetilide26$9,916
Metoprolol Succinate312$4,877
Midodrine Hcl45$4,841
Flecainide Acetate70$2,902
Losartan Potassium270$2,835
Nebivolol Hcl36$2,188
Amiodarone Hcl117$2,175
Digoxin26$1,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$307$499,496412 claims
Johnson & JohnsonXarelto$1,528$314,362269 claims
NovartisEntresto$617$139,512100 claims
Boehringer IngelheimJardiance$122$117,79791 claims
Sanofi-aventis U.S. LLCMultaq$29$18,51711 claims
AmgenCorlanor$13$12,71415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →